Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 11/20 | 0.46 |
| ▸ | MMP2 | P08253 | 10/20 | 0.46 |
| ▸ | MMP1 | P03956 | 6/20 | 0.46 |
| ▸ | MMP8 | P22894 | 5/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.36 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.36 |
| ▸ | SDCBP | O00560 | 1/20 | 0.36 |
| ▸ | SDC2 | P34741 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870400 | 0.94 | HDAC8 (0.46) | MMP9MMP2MMP1MMP8HDAC8 | |
| SCHEMBL5870407 | 0.83 | HDAC8 (0.41) | MMP9MMP2MMP1MMP8HDAC8 | |
| SCHEMBL5870582 | 0.81 | MMP9 (0.41) | MMP9MMP2MMP1MMP8 | |
| SCHEMBL5870540 | 0.79 | HDAC8 (0.45) | HDAC8NPC1RAB9A | |
| SCHEMBL6956963 | 0.78 | MMP1 (0.35) | MMP9MMP2MMP1MMP8 | |
| SCHEMBL5870248 | 0.74 | PSMB5 (0.43) | MMP2MMP1 | |
| SCHEMBL6753432 | 0.74 | HDAC8 (0.45) | MMP9MMP2MMP1MMP8HDAC8 | |
| SCHEMBL4457969 | 0.73 | HDAC8 (0.44) | HDAC8 | |
| SCHEMBL6294772 | 0.73 | HDAC8 (0.39) | MMP9MMP2MMP1MMP8HDAC8 | |
| SCHEMBL5870406 | 0.71 | NAAA (0.41) | MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132449-B2 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2006-11-07 | — | — | US | disclosed |
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPUTICS LIMITED (GB) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127424-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | MMP9 356/4885MMP2 94/4885MMP1 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.